GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Deciphera Pharmaceuticals Inc (FRA:D05) » Definitions » Cash Receipts from Deposits by Banks and Customers

Deciphera Pharmaceuticals (FRA:D05) Cash Receipts from Deposits by Banks and Customers


View and export this data going back to 2017. Start your Free Trial

What is Deciphera Pharmaceuticals Cash Receipts from Deposits by Banks and Customers?

Cash Receipts from Deposits by Banks and Customers only applicable to companies reporting Cash Flow from Operations in direct method.


Deciphera Pharmaceuticals (FRA:D05) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Deciphera Pharmaceuticals Inc (FRA:D05) » Definitions » Cash Receipts from Deposits by Banks and Customers
Traded in Other Exchanges
Address
200 Smith Street, Waltham, MA, USA, 02451
Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.